Balance Sheet
Includes Current Assets, Liabilities and Stockholder's Equity
Quarter Ended Mar 31, 2020
As of March 31, 2020, Adaptimmune had cash and cash equivalents of $86.4 million and Total Liquidity of $196.4 million.
Revenue for the first quarter ended March 31, 2020 was $0.7 million.
For Fiscal Year Ending Dec 31, 2019
For complete information regarding our financials, see our periodic filings